Absorption of azithromycin from the gastrointestinal tract is rapid, this process is due to the fact that the substance has lipophilicity and resistance to an acidic medium. With the use of 500 mg of LS, the peak plasma index is observed after 2.5-2.96 hours and equal to 0.4 mg / l. The level of bioavailability is 37%.
The substance is well distributed inside the tissues and organs of the genitourinary system (this includes the prostate), respiratory organs, subcutaneous layer and skin. The level of concentration inside the tissues is higher than inside the plasma (10-50 times), which is due to (together with a long half-life) the weak synthesis of azithromycin with a plasma protein, and in addition the ability of the component to pass into the eukaryotic cells and accumulate in a medium with a low index The pH that surrounds the lysosomes. Such properties contribute to high indicators of the distribution volume (31.1 l / kg) and clearance within the plasma.
The ability of the active substance to accumulate mainly within the lysosomes is very important for the processes of elimination of bacterial pathogens within cells. It was revealed that the phagocytes move the medicine to the site of inflammation, where it is released by phagocytosis. The level of concentration of the component inside the infectious foci is higher than inside the healthy tissues (mean - 24-34%) and correlates with the severity of puffiness. Although azithromycin is found in large numbers inside phagocytes, it does not have a significant effect on their activity.
Bactericidal indices of the substance remain inside the inflammatory foci in the period of 5-7 days after the use of the last dosage. This allows the use of short-term therapeutic courses (for 3 or 5 days).
Excretion of the component from the plasma is carried out in 2 stages: the half-life is 14-20 hours (in the interval 8-24 hours after the capsule is consumed) and the 41st hour (in the interval 24-72 hours) for which the reception of drugs can occur once per day.
, , , , , ,